Malin Corp. Plc. invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. Its priority assets includes Poseida, Immunocore, Kymab and Viamet. The company was founded on December 16, 2014 and is headquartered in Dublin, Ireland.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company